| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Apyx Medical Corporation$4.12
+0.04 (+0.98%)
F 16Pipeline Score MedTech · Commercial
Market Cap
161.21 M
EPS
-0.22
P/E Ratio
-17.47 $
Value Trade
301.37 K
SEC Financials
Q1 2026Dilution Risk
Revenue
12.49 M
R&D Expenses
765.00 K
Operating CF
-572.00 K
Total Assets
63.02 M
Total Liabilities
49.94 M
Equity
12.83 M
D/E Ratio
12,345
-1.67 %
Week
5.36 %
1 Month
10.43 %
3 Month
0.49 %
6 Month
-60.55 %
5 Year
450.67 %
All Time
Cash Data
Cash Position
31.14 M
Monthly Burn
191.00 K
Runway
161.6 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
78.42 K
52 Week Range
1.49 - 4.50
% held by Insiders
14.34 %
% held by Institutions
49.7 %
Enterprise Value
169.79 M
Total Shares
41.84 M
Short %
0.66 %
Float Shares
32.26 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 14%
Micro Cap (rank 779 of 905)
Percentile RankApyx Medical Corporation has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in APYX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
APYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
APYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
APYX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
APYX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
APYX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
APYXBody by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
Apyx Medical Corporation will showcase its Body by Apyx at Miami Swim Week, highlighting real patient transformations. The event will feature the AYON Body Contouring System, which integrates various body contouring technologies. This initiative aims to reshape beauty standards and meet the growing demand for body contouring procedures, emphasizing authenticity and patient journeys.
Read more →APYXApyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
Apyx Medical Corporation announced a new retrospective study published in 'Plastic and Reconstructive Surgery - Global Open', evaluating the benefits of Renuvion when combined with liposuction. The study found that patients using Renuvion reported higher satisfaction with their abdominal appearance and experienced lower rates of abdominoplasty and surgical revisions, while complication rates remained comparable to traditional methods.
Read more →APYXApyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Apyx Medical Corporation has received expanded FDA 510(k) clearance for its AYON Body Contouring System, now including power liposuction capabilities. This advancement aims to improve surgical efficiency and reduce operating room time. The company plans a limited commercial launch to enhance training and customer experience before broader adoption.
Read more →APYXApyx Medical Corporation Reports First Quarter 2026 Financial Results
Apyx Medical Corporation reported a total revenue of $12.5 million for Q1 2026, marking a 36% increase in its Surgical Aesthetics segment. The company raised its revenue guidance for the full year to between $59.0 million and $60.0 million. Despite a net loss of $2.1 million, the company remains optimistic about its growth, particularly in international markets like South Korea.
Read more →APYXApyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
Apyx Medical Corporation will announce its financial results for the first quarter of fiscal year 2026 on May 7, 2026. The announcement will be followed by a conference call at 8:00 a.m. ET, where management will discuss the results and answer questions. The company specializes in surgical aesthetics, offering innovative products like Renuvion and the AYON Body Contouring System.
Read more →APYXRenuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"
Apyx Medical Corporation's Renuvion has won the NewBeauty Award for "Best Minimally Invasive Skin Tightener" for the second consecutive year. This recognition highlights the device's effectiveness in body contouring and its role in enhancing patient confidence. Renuvion is noted for being the only FDA-cleared technology for use after liposuction, further solidifying its position in the market.
Read more →APYXApyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Apyx Medical Corporation reported strong financial results for Q4 and the full year of 2025, with total revenue reaching a record $19.2 million. The company attributed its success to substantial growth in its Surgical Aesthetics segment, particularly from the AYON Body Contouring System. However, while the Surgical Aesthetics segment saw nearly 50% growth in U.S. sales, net losses persisted at $1.3 million for the quarter. Looking ahead, Apyx expects total revenue for FY2026 to fall between $57.5 million and $58.5 million.
Read more →APYXApyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026
Apyx Medical Corporation announced it will release its fourth quarter financial results for fiscal year 2025 on March 10, 2026. A conference call will follow at 8:00 a.m. ET, allowing stakeholders to discuss the results. The company is known for its innovative surgical aesthetics products, including Renuvion and the AYON Body Contouring System.
Read more →APYXApyx Medical Corporation to Participate in The Citizens Life Sciences Conference
Apyx Medical Corporation announced its participation in The Citizens Life Sciences Conference on March 11, 2026, in Miami, FL. CEO Charlie Goodwin and CFO Matt Hill will engage in a fireside chat and hold one-on-one meetings with investors. The event will be accessible via live webcast, with a replay available later.
Read more →APYXApyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Apyx Medical Corporation announced its participation in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference scheduled for February 10, 2026, in Snowbird, Utah. The company is known for its innovative surgical aesthetics products, including Renuvion and the AYON Body Contouring System. Investors can request meetings through their BTIG representatives.
Read more →APYXApyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
Apyx Medical Corporation has announced preliminary revenue results for the fourth quarter and full year of 2025, showcasing a strong increase in total revenues. For Q4 2025, the total revenue is projected to be around $19 million, signifying a 34% year-over-year increase. The company's Surgical Aesthetics revenue also displayed a notable rise of approximately 38%. However, the OEM revenue experienced a decline of 21% year-over-year, highlighting areas of concern amidst overall growth.
Read more →APYXApyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea
Apyx Medical Corporation has announced the approval and commercial launch of its Apyx One console and single-use handpieces in South Korea, following regulatory approval from the Ministry of Food and Drug Safety. The company is set to start shipping these products in the fourth quarter of 2025. The Apyx One console features a multifunctional design aimed at enhancing cosmetic surgical procedures. With South Korea's cosmetic surgery market expected to reach $3.9 billion by 2033, Apyx plans to cater to the increasing demand for body contouring technologies.
Read more →APYXApyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock
Apyx Medical Corporation has announced the pricing of its public offering of 2,762,431 shares at $3.62 per share, set to close around November 19, 2025. The company aims to use the net proceeds for working capital and general corporate purposes. This offering is part of a shelf registration statement and reflects the company's commitment to expanding its market presence. Lucid Capital Markets is acting as the sole manager for the offering, which includes an underwriter option for additional shares.
Read more →APYXApyx Medical Corporation Announces Proposed Public Offering of Common Stock
Apyx Medical Corporation announced the commencement of an underwritten public offering of its common stock. The offering is subject to market conditions and will be made pursuant to a shelf registration statement filed with the SEC. Specific details regarding the size and terms of the offering remain unclear. The company is known for its innovative surgical aesthetics products, including Renuvion and the AYON Body Contouring System.
Read more →APYXApyx Medical Corporation Reports Third Quarter 2025 Financial Results
Apyx Medical Corporation reported a 19% increase in Surgical Aesthetics revenue for Q3 2025, driven by the AYON Body Contouring System's successful commercialization. The company is optimistic about future growth, particularly with the anticipated FDA clearance for power liposuction functionality. Despite a net loss of $2.0 million, overall financial performance showed improvement compared to the previous year.
Read more →APYXApyx Medical Corporation to Participate in Upcoming November Investor Conferences
Apyx Medical Corporation will participate in two upcoming investor conferences in November 2025. CEO Charles Goodwin and CFO Matt Hill will attend the Craig-Hallum Alpha Select Conference and the Canaccord Genuity MedTech Forum. These events provide an opportunity for investors to engage with company leadership and learn more about Apyx's innovative technologies.
Read more →APYXApyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
Apyx Medical Corporation has announced that it will release its financial results for the third quarter of fiscal year 2025 on November 6, 2025, before the market opens. A conference call will follow at 8:00 a.m. Eastern Time on the same day, where management will discuss the results and answer questions. Apyx Medical's innovative products, such as Renuvion® and the AYON Body Contouring System™, continue to gain traction in the cosmetic surgery market, supported by numerous clinical publications.
Read more →APYXApyx Medical Corporation Submits FDA 510(k) for Device Label Expansion of AYON Body Contouring System™ for Power Liposuction
Apyx Medical Corporation has submitted a 510(k) premarket notification to the FDA for the AYON Body Contouring System, aiming to expand its label to include power liposuction. This expansion could establish AYON as the first fully integrated body contouring system, enhancing surgical workflows and patient outcomes. The company is also hosting a virtual event to discuss the commercial launch.
Read more →APYXApyx Medical to Host Virtual Key Opinion Leader Event to Discuss the Commercial Launch of The AYON Body Contouring System™ on October 14, 2025
Apyx Medical Corporation will host a virtual event on October 14, 2025, to discuss the launch of its AYON Body Contouring System. This system integrates advanced technology for body contouring and is the first FDA-cleared all-in-one platform for aesthetic surgical suites. The event will feature Dr. Paul Vanek, a leading expert in the field.
Read more →APYXApyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apyx Medical Corporation announced the granting of a nonstatutory stock option for 100,000 shares to John Featherstone, VP of North American Sales, as an inducement for employment. The option, priced at $1.85, vests over four years. This move aligns with Nasdaq regulations and reflects the company's commitment to its workforce amidst ongoing market challenges.
Read more →APYXApyx Medical Expands Global Sales Leadership with Strategic Hires to Support AYON Launch and Accelerated Growth
Apyx Medical Corporation announced the strategic appointments of two sales executives to enhance its global sales leadership ahead of the launch of the AYON Body Contouring System. John Featherstone has been appointed Vice President of North American Sales, while Simon Davies serves as Director of International Sales for Europe and Asia-Pacific. Their extensive experience in the aesthetic and medical device industries is expected to support Apyx's commercial growth and market penetration. The company aims to leverage their leadership to accelerate the adoption of both AYON and Renuvion products.
Read more →APYXApyx Medical Corporation Reports Second Quarter 2025 Financial Results
Apyx Medical Corporation reported its financial results for the second quarter of 2025, disclosing total revenue of $11.4 million, which was a decline from $12.1 million in the same quarter of 2024. Despite this decrease, the company successfully launched its AYON Body Contouring System and received positive responses from surgeons ahead of its September commercial launch. The financial guidance for FY2025 has been revised upwards, and the company achieved a significant reduction in net loss. In addition, Apyx began commercial sales of its Renuvion product in China, which has garnered strong interest among clinicians.
Read more →APYXApyx Medical Corporation to Participate in the Canaccord Genuity 45th Annual Growth Conference
Apyx Medical Corporation will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. CEO Charlie Goodwin and CFO Matt Hill will engage in a fireside chat and hold one-on-one meetings with investors. The event highlights Apyx's innovative helium plasma technology and its applications in cosmetic surgery.
Read more →APYXApyx Medical Corporation Announces Launch of Renuvion® in China
Apyx Medical Corporation has launched its Renuvion product in China, marking a key step in its international expansion strategy. The company has partnered with GlamMoon Medical Technology for distribution following initial market clearance. Early responses from physicians have been positive, highlighting the demand for advanced medical solutions in the Chinese market.
Read more →APYXApyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
Apyx Medical Corporation plans to release its financial results for the second quarter of fiscal year 2025 on August 7, 2025, after market closure. The management will conduct a conference call at 4:30 p.m. Eastern Time to discuss the results and answer questions from participants. Interested individuals can join by phone or through a live webcast. Apyx Medical is known for its advanced energy technology products, including the Renuvion and AYON Body Contouring System.
Read more →APYXApyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™
Apyx Medical Corporation has announced that it has received FDA clearance for the AYON Body Contouring System, marking a significant advancement in the aesthetic surgical suite. The system integrates multiple functions, including fat removal and tissue contraction, designed to enhance the efficacy of body contouring procedures. Apyx Medical plans to begin commercial launches in key geographies targeting opinion leader surgeons by the second half of 2025. This new product aligns with anticipated growth in body contouring procedures as more patients seek solutions for post-weight loss skin issues.
Read more →APYXApyx Medical Corporation Reports First Quarter 2025 Financial Results
Apyx Medical Corporation reported its financial results for the first quarter of 2025, highlighting a total revenue of $9.4 million, an 8% decrease from the previous year. Despite the decline in overall revenue, the Advanced Energy segment saw a 6% increase driven by strong sales of single-use handpieces. Notably, the company achieved a 45% reduction in net loss compared to Q1 2024, indicating improved financial health. Apyx continues to prepare for the launch of its AYON Body Contouring System later in 2025, pending FDA clearance.
Read more →APYXApyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures
Apyx Medical Corporation announced the publication of two peer-reviewed studies that demonstrate favorable clinical outcomes for its Renuvion device during body contouring procedures, such as lipoabdominoplasty. Both studies indicate that patients using Renuvion experienced greater improvements in abdominal skin laxity and higher satisfaction without increasing complication rates. The findings are expected to support the growing demand for aesthetic treatments as more individuals seek solutions for skin laxity resulting from rapid weight loss. The company is positioned to cater to this expanding patient population with its FDA-cleared device.
Read more →APYXApyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025
Apyx Medical Corporation has announced that it will release its financial results for the first quarter of fiscal year 2025 on May 8, 2025. The company will conduct a conference call to discuss these results and engage in a question-and-answer session. This event underscores the company's ongoing operations and communication efforts with investors.
Read more →APYXApyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
Apyx Medical Corporation (NASDAQ: APYX) reported its fourth quarter and full year 2024 financial results, showing a 5% increase in shipped handpiece units, with a substantial 20% growth in the U.S. The company achieved total revenue of $14.2 million for Q4 2024, despite an overall revenue decline of 8% for the year. Apyx submitted a 510(k) premarket notification to the U.S. FDA for their AYON Body Contouring System, which is set to launch in late 2025. Management noted improved financial performance characterized by a significant reduction in net loss and plans for cost-saving measures to streamline operations.
Read more →APYXApyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025
Apyx Medical Corporation announced that it will release its financial results for the fourth quarter and fiscal year 2024 on March 13, 2025, prior to market opening. A conference call will follow at 8:30 a.m. ET to discuss these results and engage in a question-and-answer session. The call can be accessed by phone and will also be available via a live webcast. Apyx Medical is known for its innovative Helium Plasma technology products.
Read more →APYXApyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results
Apyx Medical Corporation reported preliminary revenue results for the fourth quarter and full year 2024, indicating a decline in total revenues. The fourth quarter total revenue is estimated to be between $14.1 to $14.3 million, while the full-year revenue is projected to be approximately $48.0 to $48.2 million, both showing a year-over-year decrease. Despite these declines, the company highlighted significant growth in its Advanced Energy segment and strong future potential with the forthcoming AYON™ Body Contouring System, which is anticipated to launch pending FDA clearance.
Read more →APYXApyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™
Apyx Medical Corporation has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, aimed at providing comprehensive solutions for body contouring procedures. The system combines various advanced technologies, including dual aspiration and ultrasound-assisted liposuction, to address a wide range of patient aesthetic needs. The company anticipates additional submissions to expand the device's indications later in the year. CEO Charlie Goodwin expressed optimism about the system's potential to establish Apyx as a leader in the aesthetic surgical market.
Read more →APYXApyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference
Apyx Medical Corporation, known for its helium plasma and radiofrequency platform technology, is set to participate in the Piper Sandler 36th Annual Healthcare Conference in New York on December 4, 2024. CEO Charlie Goodwin and CFO Matt Hill will present in a fireside chat and engage in one-on-one meetings with investors throughout the day. The company's innovative products, Renuvion and J-Plasma, are designed for both cosmetic and hospital surgical markets and have a strong clinical backing.
Read more →APYXApyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference
Apyx Medical Corporation, known for its Renuvion helium plasma and radiofrequency platform technology, is set to attend the 15th Annual Craig-Hallum Alpha Select Conference. The event will take place on November 19, 2024, in New York City, where CEO Charles Goodwin and CFO Matt Hill will hold 1x1 meetings with investors. The company emphasizes its innovative products in the cosmetic and hospital surgical markets and invites interested parties to schedule meetings through their representatives.
Read more →APYXApyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering
Apyx Medical Corporation has announced a successful registered direct offering, securing approximately $7,000,000. The company will sell 3,000,000 shares at a price of $1.18 per share, alongside pre-funded warrants for additional shares. The offering aims to bolster working capital and support general corporate initiatives. Following the closing on November 8, 2024, the company emphasizes no placement agent was involved in the transaction, reflecting investor confidence.
Read more →APYXApyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook Strengthened balance sheet with a common stock registered di
Apyx Medical Corporation has reported its financial results for the third quarter of 2024, highlighting a decline in overall revenue but an increase in single-use handpiece sales. The company raised $7 million to enhance its balance sheet and introduced a new product, the Ayon body contouring system, expected to launch in late 2025. Despite a decrease in revenue for the Advanced Energy segment, the company remains optimistic about future growth driven by new product developments and cost-saving initiatives.
Read more →APYXApyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024
Apyx Medical Corporation announced the release date for its third quarter fiscal year 2024 financial results, set for November 8, 2024. A conference call will be held that same morning to discuss the results and include a question-and-answer session for shareholders. The company, known for its Renuvion and J-Plasma products, emphasizes its commitment to innovation in medical technology.
Read more →APYXApyx Medical Corporation Reports Second Quarter 2024 Financial Results Updates Full Year 2024 Financial Outlook CLEARWATER, FL
Apyx Medical Corporation reported its second quarter 2024 financial results, highlighting a total revenue decline of 10% year-over-year to $12.1 million. While advanced energy revenue decreased significantly, OEM revenue saw a 29% increase. The company faces challenges in the cosmetic surgery market, contributing to a notable increase in net loss to $6.6 million. Despite these difficulties, management remains optimistic about growing sales in their handpiece segment and the potential impact of their new marketing initiatives.
Read more →APYXApyx Medical Corporation Reports First Quarter 2024 Financial Results Reaffirms Full Year 2024 Financial Outlook CLEARWATER, FL
Apyx Medical Corporation reported a 16% decrease in total revenue for Q1 2024, amounting to $10.2 million. The company's Advanced Energy segment faced a substantial 23% decline in revenue, leading to a net loss of $7.6 million, which represents a 118% increase in losses compared to the previous year. Despite these challenges, Apyx reaffirmed its financial outlook for the full year 2024, projecting total revenue in the range of $49.7 million to $52.9 million. The company is focusing on leveraging new clinical indications and products to enhance market awareness and drive future growth.
Read more →APYXApyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results Introduces Full Year 2024 Financial Outlook Advanced Energy Sales increased 15% year-over-year and 23% quarter-over-quarter in the four
Apyx Medical Corporation has reported its financial results for Q4 and the full year of 2023, showcasing a total revenue increase of 16% year-over-year for the fourth quarter, reaching $14.7 million. The Advanced Energy segment brought in $12.1 million, marking a 15% growth. However, the company also faced challenges as net losses increased by 59% in the fourth quarter. Looking forward, Apyx has introduced its financial outlook for 2024, anticipating continued growth while managing resource allocation amid a challenging capital equipment purchasing environment.
Read more →APYXApyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting Presentation hosted by Dr. Michael Kluska to feature the results of
Apyx Medical Corporation announced that its Renuvion technology will be showcased in multiple educational sessions at the American Academy of Cosmetic Surgery's 40th Annual Scientific Meeting from February 22-24, 2024. Dr. Michael Kluska will present a retrospective clinical study comparing Renuvion with a competing technology, demonstrating a superior safety profile with significantly fewer adverse events for the former. This event aims to raise awareness about the benefits of Apyx's Helium Plasma Technology in cosmetic procedures.
Read more →APYXApyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion Following Liposuction in Multiple Areas of the Body Analysis of data from 483 patients with a total of 1,184 body ar
Apyx Medical Corporation announced a peer-reviewed study published in the Aesthetic Surgery Journal Open Forum that assessed the safety of Renuvion following liposuction. The study analyzed data from 483 patients and found no new or increased risks associated with the use of Renuvion compared to liposuction alone. This publication reinforces the safety profile of Renuvion, which is now cleared by the FDA for use in cosmetic procedures. The results are expected to contribute positively to the clinical credibility of Renuvion in the aesthetic surgery market.
Read more →APYXApyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results CLEARWATER, FL
Apyx Medical Corporation has reported preliminary revenue figures for the fourth quarter and full year of 2023, indicating growth in revenues across its segments. Total revenue for the fourth quarter is projected to be between $14.2 million and $14.6 million, showing a year-over-year increase. Advanced Energy revenue is expected to grow similarly, although the segment faced challenges in new customer sales due to a cautious purchasing environment. The company plans to release detailed financial results in March 2024.
Read more →APYXApyx Medical Corporation Announces New Debt Facility with Perceptive Advisors New facility includes senior, secured term loans of up to $45 million CLEARWATER, FL
Apyx Medical Corporation has announced a new five-year credit agreement with Perceptive Advisors, providing a facility of up to $45 million. The initial loan of $37.5 million was fully drawn at closing, which will help strengthen the company's balance sheet and enhance its financial flexibility. The debt facility includes a delayed draw loan option and features interest-only payments for the first 48 months. This strategic financing decision aims to support Apyx's ongoing operations and product development in the healthcare sector.
Read more →APYXApyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook Advanced Energy Sales increased 39% year-over-year in Q3 CLEARWATER, FL
Apyx Medical Corporation reported robust financial results for Q3 2023, with total revenues of $12.0 million, marking a 31% year-over-year increase. Advanced Energy sales saw a significant rise of 39%, attributed to global sales of new products and FDA clearances. Despite these gains, the company reported a net loss of $4.6 million, but improved on the previous year's figure. Additionally, Apyx secured a new credit facility of up to $45 million, expected to enhance its financial position.
Read more →APYXApyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook Advanced Energy Sales increased 40% year-over-year in Q2 CLEARWATER, FL
Apyx Medical Corporation reported a strong financial performance for Q2 2023, with total revenue increasing by 32% to $13.6 million, primarily driven by a 40% growth in Advanced Energy sales. The company also reaffirmed its optimistic full-year outlook, citing successful FDA clearances for its Renuvion technology. However, OEM revenue experienced a decline of 4%, and international sales did not meet expectations, suggesting areas for improvement. The company achieved significant reductions in net loss, reflecting positive trends in financial performance.
Read more →APYXApyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook CLEARWATER, FL
Apyx Medical Corporation reported its financial results for the first quarter of 2023, revealing total revenue of $12.1 million, a decline of 3% compared to the same period last year. Despite a 10% drop in Advanced Energy revenue, the company is optimistic, raising its full-year financial guidance based on stronger-than-expected domestic sales driven by the newly launched Apyx One Console. Additionally, the company has received multiple FDA clearances for its Renuvion technology, signaling expanded market opportunities and product enhancements.
Read more →APYXApyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results Introduces Full Year 2023 Financial Outlook CLEARWATER, FL
Apyx Medical Corporation reported its financial results for the fourth quarter and full year of 2022, showing a decline in total revenue of 25% year-over-year for Q4. The company's net loss for Q4 increased to $6.0 million and the full year's revenue saw an overall dip of 8%. In response to these challenges, Apyx announced the launch of a direct-to-consumer campaign and the introduction of its Apyx One Console generator, along with the submission of a 510(k) notification to the FDA aimed at expanding product usage. Despite these hurdles, the company remains optimistic about growth prospects in 2023 supported by an expanding portfolio and recent financing arrangements.
Read more →APYXApyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial Facility includes a senior, secured term loan of up to $25 million and a revolving line of credit of up to $10 million CLEARWATER, F
Apyx Medical Corporation has announced a new five-year credit agreement with MidCap Financial, allowing access to up to $35 million in secured financing. The facility consists of a senior, secured term loan of up to $25 million and a revolving credit line of up to $10 million. The funding will enhance the company's financial flexibility and support its strategic growth initiatives. The term loan features interest-only payments for an initial period, along with specified conditions for additional draws.
Read more →APYXApyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results CLEARWATER, FL
Apyx Medical Corporation announced preliminary revenue results for Q4 and the full year of 2022, indicating significant year-over-year declines in total revenue and Advanced Energy revenue. Despite the downturn, the OEM segment experienced growth. The company attributes the revenue decline to ongoing disruptions from a Medical Device Safety Communication and reports that global sales in Advanced Energy improved sequentially. Apyx also focuses on potential growth through regulatory engagement with the FDA regarding its Renuvion technology.
Read more →APYXApyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook CLEARWATER, FL
Apyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook CLEARWATER, FL - November 10, 2022 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency tec
Read more →APYXApyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook CLEARWATER, FL
Apyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook CLEARWATER, FL - August 11, 2022 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency techn
Read more →APYXAPYX FINAL DEADLINE FRIDAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Apyx Medical Corporation Investors to Secure Counsel Before Important August 5 Deadline in Securities Class Action – APYX
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both dates inclusive (the “Class Period”), of the important
Read more →APYXAPYX MEDICAL CORPORATION (NASDAQ: APYX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apyx Medical Corporation (NASDAQ: APYX)
Did you lose money on investments in Apyx Medical? If so, please visit Apyx Medical Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Bernstein Lieb
Read more →APYXApyx Medical Corporation Investors: Last Days to Actively Participate in the Class Action Lawsuit; August 5, 2022; Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) investors that a class action has been filed on
Read more →APYXAPYX FINAL DEADLINE ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages Apyx Medical Corporation Investors with Losses to Secure Counsel Before Important August 5 Deadline in Securities Class Action – APYX
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both dates inclusive (the “Class Period”), of the important
Read more →APYXAPYX DEADLINE NOTICE: NATIONALLY RANKED ROSEN LAW FIRM Encourages Apyx Medical Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action – APYX
NEW YORK, July 23, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both dates inclusive (the “Class Period”), of the importa
Read more →APYXAPYX SHAREHOLDER ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Apyx Medical Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – APYX
NEW YORK, July 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both dates inclusive (the “Class Period”), of the important
Read more →APYXApyx Medical Corp. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 27, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Apyx Medical Corporation (NASDAQ: APYX) investors that the firm has initiated an investigation into possible sec
Read more →APYXApyx Medical Corporation Shareholder Update: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Apyx Medical Corporation (APYX)
SAN DIEGO, June 14, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Apyx Medical Corporation (NASDAQ: APYX) securities b
Read more →APYXAPYX MEDICAL CORPORATION CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of Florida against Apyx Medical Corporation
NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Middle District of Florida on behalf of persons and entities that purchased or
Read more →APYXAPYX MEDICAL CORPORATION (NASDAQ: APYX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Apyx Medical Corporation (NASDAQ: APYX)
Did you lose money on investments in Apyx Medical? If so, please visit Apyx Medical Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Bernstein Lieb
Read more →APYXApyx Medical Corporation Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook Advanced Energy sales increased 41% year-over-year in Q1 CLEARWATER, FL
Apyx Medical Corporation Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook Advanced Energy sales increased 41% year-over-year in Q1 CLEARWATER, FL - May 12, 2022 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), a maker of medical
Read more →APYXAPYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Apyx Medical Corp. on Behalf of Apyx Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Apyx Medical Corp. (“Apyx” or the “Company”) (NASDAQ: APYX) on behalf of Apyx stockholders. Our investigation c
Read more →APYXApyx Medical Corporation Reports Fourth Quarter and Full Year 2021 Financial Results Introduces Full Year 2022 Financial Outlook Advanced Energy Sales increased 52% year-over-year in Q4 up 94% year-over-year in 2021 CLEA
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2021 Financial Results Introduces Full Year 2022 Financial Outlook Advanced Energy Sales increased 52% year-over-year in Q4 up 94% year-over-year in 2021 CLEARWATER, FL - March 17, 2022 - Apyx Medical Corporation (NA
Read more →APYXApyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 88% year-over-year in Q3 CLEARWATER, FL
Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 88% year-over-year in Q3 CLEARWATER, FL - November 11, 2021 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), a maker of medical devi
Read more →APYXApyx Medical Corporation Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 248% year-over-year in Q2 CLEARWATER, FL
Apyx Medical Corporation Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 248% year-over-year in Q2 CLEARWATER, FL - August 12, 2021 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), a maker of medical devi
Read more →APYXApyx Medical Corporation Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 92% year-over-year in Q1 CLEARWATER, FL - MAY 12, 2021 - Apyx Medical Corporation (
Apyx Medical Corporation Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 92% year-over-year in Q1 CLEARWATER, FL - MAY 12, 2021 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), a maker of medical devices a
Read more →APYXApyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results Introduces Full Year 2021 Financial Outlook Advanced Energy Sales increased 44% year-over-year in Q4 CLEARWATER, FL - MARCH 31, 2021 -
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results Introduces Full Year 2021 Financial Outlook Advanced Energy Sales increased 44% year-over-year in Q4 CLEARWATER, FL - MARCH 31, 2021 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), a
Read more →APYXApyx Medical Corporation Reports Third Quarter 2020 Financial Results CLEARWATER, FL - NOVEMBER 9, 2020 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), a maker of medical devices and supplies and the developer
Apyx Medical Corporation Reports Third Quarter 2020 Financial Results CLEARWATER, FL - NOVEMBER 9, 2020 - Apyx Medical Corporation (NASDAQ APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion
Read more →APYXApyx Medical Corporation Reports First Quarter 2020 Financial Results CLEARWATER, FL - MAY 11, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of H
Apyx Medical Corporation Reports First Quarter 2020 Financial Results CLEARWATER, FL - MAY 11, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion in t
Read more →APYXAPYX ALERT: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Apyx Medical Corporation – APYX
NEW YORK, March 25, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) resulting from allegations that Apyx may have issued materiall
Read more →APYXApyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook Advanced Energy Sales increase 58% year-ove
Apyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook Advanced Energy Sales increase 58% year-over-year in Q4 and increase 73% year-over-year in FY'19 CLEA
Read more →APYXApyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2019 Revenue Results Advanced Energy Sales of approximately $6.6 to $6.9 million in Q4, up 52% to 58% year-over-year CLEARWATER, FL - JANUARY 13,
Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2019 Revenue Results Advanced Energy Sales of approximately $6.6 to $6.9 million in Q4, up 52% to 58% year-over-year CLEARWATER, FL - JANUARY 13, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the "Compan
Read more →APYXApyx Medical Corporation Announces Subject Enrollment Initiated in New Study Evaluating the Use of Renuvion Technology in Dermal Resurfacing Procedures
Apyx Medical Corporation Announces Subject Enrollment Initiated in New Study Evaluating the Use of Renuvion Technology in Dermal Resurfacing Procedures CLEARWATER, FL - DECEMBER 3, 2019 - Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the "Company")
Read more →APYXApyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $6.1 million in Q3 , up 104% year-over-year CLEARWATER, FL - NOVEMBER 11, 2019 - Apyx
Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $6.1 million in Q3, up 104% year-over-year CLEARWATER, FL - NOVEMBER 11, 2019 - Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a make
Read more →APYXApyx Medical Corporation Announces Subject Enrollment Initiated in Study Evaluating the Use of Renuvion Technology in Skin Laxity Procedures in the Neck and Submental Region
Apyx Medical Corporation Announces Subject Enrollment Initiated in Study Evaluating the Use of Renuvion Technology in Skin Laxity Procedures in the Neck and Submental Region CLEARWATER, FL - OCTOBER 14, 2019 - Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ
Read more →APYXApyx Medical Corporation Reports Second Quarter and First Half of 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $5.3 million in Q2 , up 69% year-over-year CLEARWATER, FL - AUGUST 7,
Apyx Medical Corporation Reports Second Quarter and First Half of 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $5.3 million in Q2, up 69% year-over-year CLEARWATER, FL - AUGUST 7, 2019 - Apyx Medical Corporation (NASDAQ:APYX) (the "Compa
Read more →APYXApyx Medical Corporation Announces Appointment of Minnie Baylor-Henry to the Company's Board of Directors
Apyx Medical Corporation Announces Appointment of Minnie Baylor-Henry to the Company's Board of Directors CLEARWATER, FL - AUGUST XX, 2019 - Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and t
Read more →APYXAPYX ALERT: Rosen, an Internationally Recognized Law Firm, Reminds Apyx Medical Corporation Investors of June 17th Deadline in the Securities Class Action; Encourages Investors with Over $100K in Losses to Contact the Firm – APYX
NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) from August 1, 2018 through April 1, 2019, inclusive (the “Class Period”) of the important June 17, 2019
Read more →APYXAPYX REMINDER: Hagens Berman Reminds Apyx Medical Corporation (APYX) Investors of Lead Plaintiff Deadline, Encourages Investors to Contact the Firm
SAN FRANCISCO, May 29, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, with nine offices in eight cities around the country and eighty attorneys, reminds investors in Apyx Medical Corporation (NASDAQ: APYX) of the June 17, 2019 Lead Plaintiff deadline in the securities
Read more →APYXAPYX JUNE 17th DEADLINE: Rosen, a Top Ranked Law Firm, Reminds Apyx Medical Corporation Investors of Important Deadline in the Securities Class Action – APYX
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation from August 1, 2018 through April 1, 2019, inclusive (the “Class Period”) of the important June 17, 2019 deadline in the
Read more →APYXAPYX DEADLINE: Pawar Law Group Reminds Investors of Deadline Securities Class Action Lawsuit Against Apyx Medical Corporation – APYX
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Apyx Medical Corporation (NASDAQ: APYX) from August 1, 2018 through April 1, 2019, inclusive (the “Class Period”). The
Read more →APYXAPYX DEADLINE ALERT: Rosen Law Firm Reminds Apyx Medical Corporation Investors of Important June 17th Deadline in the Securities Class Action; Encourages Investors with Over $100K in Losses to Contact the Firm – APYX
NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) from August 1, 2018 through April 1, 2019, inclusive (the “Class Period”) of the important June 17, 2019 d
Read more →APYXApyx Medical Corporation Reports First Quarter 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $4.4 million in Q1 , up 66% year-over-year CLEARWATER, FL - MAY 8, 2019 - Apyx Medical C
Apyx Medical Corporation Reports First Quarter 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $4.4 million in Q1, up 66% year-over-year CLEARWATER, FL - MAY 8, 2019 - Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medic
Read more →APYXAPYX CLASS ACTION ALERT: Hagens Berman Alerts Apyx Medical Corporation (APYX) Investors to Securities Class Action, Encourages Investors Who Suffered $50,000+ Losses to Contact the Firm
SAN FRANCISCO, May 01, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, with 9 offices in 8 cities around the country and 80 attorneys, alerts investors in Apyx Medical Corporation (NASDAQ: APYX) to the securities class action, Pritchard v. Apyx Medical Corporation et al
Read more →APYXAPYX DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Apyx Medical Corporation – APYX
NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Apyx Medical Corporation (NASDAQ: APYX) from August 1, 2018 through April 1, 2019, inclusive (the “Class Period”). T
Read more →APYXAPYX ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Apyx Medical Corporation – APYX
NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) -- Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Apyx Medical Corporation (NASDAQ: APYX) from August 1, 2018 through April 1, 2019, inclusive (the “Class Period”). The law
Read more →APYXAPYX MEDICAL CORPORATION INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Middle District of Florida against Apyx Medical Corporation
NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that filed a federal securities class action lawsuit has been filed in the United States District Court for the Middle District of Florida on behalf of persons and entities that purch
Read more →APYXApyx Medical Corporation Shareholder Alert – Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Apyx Medical Investors
PHILADELPHIA, April 18, 2019 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of Apyx Medical Corporation (“Apyx”) (NASDAQ: APYX) pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Apyx investors should b
Read more →APYXApyx Medical Corporation Provides Update on the Premarket Notification 510(k) Submission to the U.S.
Apyx Medical Corporation Provides Update on the Premarket Notification 510(k) Submission to the U.S. Food and Drug Administration (FDA) for Use in Dermal Resurfacing Procedures; Provides Preliminary First Quarter 2019 Revenue Results and Reaffirms 2019 Revenue Outlook CLEARWATER
Read more →APYXApyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2018 Revenue Results Advanced Energy Sales of approximately $4.4 to $4.5 million in Q4, up 43% to 47% year-over-year CLEARWATER, FL - JANUARY 7, 2
Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2018 Revenue Results Advanced Energy Sales of approximately $4.4 to $4.5 million in Q4, up 43% to 47% year-over-year CLEARWATER, FL - JANUARY 7, 2019 - Apyx Medical Corporation, formerly Bovie Medical Cor
Read more →APYXBovie Medical Corporation Announces Appointment of Tara H. Semb as Chief Financial Officer CLEARWATER, FL - DECEMBER 17, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supp
Bovie Medical Corporation Announces Appointment of Tara H. Semb as Chief Financial Officer CLEARWATER, FL - DECEMBER 17, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma , a patented surgical pr
Read more →APYXBovie Medical Corporation Announces Corporate Name Change to Apyx Medical Corporation and Plans to Transition Common Stock Listing to NASDAQ Global Select Market CLEARWATER, FL - DECEMBER 12, 2018 - Bovie Medical Corpora
Bovie Medical Corporation Announces Corporate Name Change to Apyx Medical Corporation and Plans to Transition Common Stock Listing to NASDAQ Global Select Market CLEARWATER, FL - DECEMBER 12, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devi
Read more →APYXBovie Medical Corporation Announces Future Retirement of Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary CLEARWATER, FL - NOVEMBER 13, 2018 - Bovie Medical Corporation (NYSE:BVX) (the "Company"), a maker o
Bovie Medical Corporation Announces Future Retirement of Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary CLEARWATER, FL - NOVEMBER 13, 2018 - Bovie Medical Corporation (NYSE:BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plas
Read more →APYXBovie Medical Corporation Reports Third Quarter 2018 Financial Results and Updates Fiscal Year 2018 Outlook Advanced Energy Sales of $3.0 million in Q3 , up 40% year-over-year and 92% year-to-date CLEARWATER, FL - NOVEMB
Bovie Medical Corporation Reports Third Quarter 2018 Financial Results and Updates Fiscal Year 2018 Outlook Advanced Energy Sales of $3.0 million in Q3, up 40% year-over-year and 92% year-to-date CLEARWATER, FL - NOVEMBER 1, 2018 - Bovie Medical Corporation (NYSEAMERICAN:BVX)
Read more →APYXBovie Medical Corporation Updates Fiscal Year 2018 Financial Outlook Now Expect Advanced Energy Sales Growth of 55% to 60% year-over-year CLEARWATER, FL
Bovie Medical Corporation Updates Fiscal Year 2018 Financial Outlook Now Expect Advanced Energy Sales Growth of 55% to 60% year-over-year CLEARWATER, FL - September 5, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and th
Read more →APYXBovie Medical Corporation Announces Completion of "Core" Business Segment Sale to Symmetry Surgical Inc. for Total Cash Consideration of $97 million Divestiture and Sale of the Core business segment allows the Company to
Bovie Medical Corporation Announces Completion of "Core" Business Segment Sale to Symmetry Surgical Inc. for Total Cash Consideration of $97 million Divestiture and Sale of the Core business segment allows the Company to further focus on the commercialization of Renuvion Cosmeti
Read more →APYXBovie Medical Corporation Reports Second Quarter 2018 Financial Results Advanced Energy Sales of $3.1 million in Q2 , up 72% year-over-year CLEARWATER, FL - AUGUST 1, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the "
Bovie Medical Corporation Reports Second Quarter 2018 Financial Results Advanced Energy Sales of $3.1 million in Q2, up 72% year-over-year CLEARWATER, FL - AUGUST 1, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and the
Read more →APYXBovie Medical Corporation Announces Preliminary Second Quarter 2018 Revenue Results Advanced Energy Sales increased approximately 70% year-over-year in Q2'18 CLEARWATER, FL - JULY 9, 2018 - Bovie Medical Corporation (NYS
Bovie Medical Corporation Announces Preliminary Second Quarter 2018 Revenue Results Advanced Energy Sales increased approximately 70% year-over-year in Q2'18 CLEARWATER, FL - JULY 9, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and
Read more →APYXBovie Medical Corporation Reports Fourth Quarter and Full Year 2017 Financial Results; Provides Fiscal Year 2018 Financial Outlook Advanced Energy Sales of $3.1 million in Q4 , up 219% year-over-year, driven by strong J-
Bovie Medical Corporation Reports Fourth Quarter and Full Year 2017 Financial Results; Provides Fiscal Year 2018 Financial Outlook Advanced Energy Sales of $3.1 million in Q4, up 219% year-over-year, driven by strong J-Plasma sales. CLEARWATER, FL - MARCH 12, 2018 - Bovie Med
Read more →APYXBovie Medical Corporation Announces Appointment of Craig A. Swandal to Board of Directors CLEARWATER, FL
Bovie Medical Corporation Announces Appointment of Craig A. Swandal to Board of Directors CLEARWATER, FL - March 9, 2018 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma , a patented surgical produc
Read more →APYXBovie Medical Corporation Appoints Charles D. Goodwin Chief Executive Officer; Updates 2017 Outlook Mr. Goodwin Brings Nearly 25 Years of Experience in the Medical Technology Industry to Advance the Growth and Profitabil
Bovie Medical Corporation Appoints Charles D. Goodwin Chief Executive Officer; Updates 2017 Outlook Mr. Goodwin Brings Nearly 25 Years of Experience in the Medical Technology Industry to Advance the Growth and Profitability of Bovie Medical and Drive the Commercialization of J-
Read more →APYXBovie Medical Corporation Reports Third Quarter 2017 Financial Results and Updates Fiscal Year 2017 Financial Outlook Advanced Energy Sales of $2.1 million in Q3 , up 52.0% year-over-year, driven by strong J-Plasma sales
Bovie Medical Corporation Reports Third Quarter 2017 Financial Results and Updates Fiscal Year 2017 Financial Outlook Advanced Energy Sales of $2.1 million in Q3, up 52.0% year-over-year, driven by strong J-Plasma sales. CLEARWATER, FL - NOVEMBER 2, 2017 - Bovie Medical Corpo
Read more →APYXBovie Medical Corporation Reports Second Quarter 2017 Financial Results and Reaffirms Fiscal Year 2017 Financial Outlook Advanced Energy Sales increased 137% year-over-year in Second Quarter 2017, driven by strong J-Plas
Bovie Medical Corporation Reports Second Quarter 2017 Financial Results and Reaffirms Fiscal Year 2017 Financial Outlook Advanced Energy Sales increased 137% year-over-year in Second Quarter 2017, driven by strong J-Plasma sales. CLEARWATER, FL - AUGUST 2, 2017 - Bovie Medica
Read more →APYXBovie Medical Corporation Reports First Quarter 2017 Financial Results and Introduce Fiscal Year 2017 Financial Outlook CLEARWATER, FL - MAY 15, 2017 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of
Bovie Medical Corporation Reports First Quarter 2017 Financial Results and Introduce Fiscal Year 2017 Financial Outlook CLEARWATER, FL - MAY 15, 2017 - Bovie Medical Corporation (NYSEMKT:BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma
Read more →APYXBOVIE MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2016 RESULTS -Record Full Year Sales Increased 24% Reflecting Strong Growth in Each Key Product Group- -Significant Gross Margin Expansion Driven By Favorabl
BOVIE MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2016 RESULTS -Record Full Year Sales Increased 24% Reflecting Strong Growth in Each Key Product Group- -Significant Gross Margin Expansion Driven By Favorable Product Mix- Fourth Quarter Highlights Full Year 2016
Read more →APYXBovie Medical Prices Public Offerings of Common Stock CLEARWATER, FL
Bovie Medical Prices Public Offerings of Common Stock CLEARWATER, FL November 10, 2016 Bovie Medical Corporation (NYSEMKT:BVX) (the Company ), a maker of medical devices and supplies and the developer of J-Plasma , a patented new surgical product, announced today the pricing of
Read more →APYXUnassociated Document BOVIE MEDICAL CORPORATION REPORTS SECOND QUARTER AND FIRST HALF 2016 RESULTS Financial and Operating Highlights Second quarter revenue increased 27.8% year-over-year, driven by strong
BOVIE MEDICAL CORPORATION REPORTS SECOND QUARTER AND FIRST HALF 2016 RESULTS Financial and Operating Highlights Second quarter revenue increased 27.8% year-over-year, driven by strong demand across the Company's product categories J-Plasma revenues more than doubled sequentia
Read more →APYXhtm BOVIE MEDICAL CORPORATION REPORTS FIRST QUARTER 2016 RESULTS First Quarter Highlights Total revenue increased 26.9% Gross margin was 42.7% J-Plasma revenues increased 25.8% year-on-year; Posi
BOVIE MEDICAL CORPORATION REPORTS FIRST QUARTER 2016 RESULTS First Quarter Highlights Total revenue increased 26.9% Gross margin was 42.7% J-Plasma revenues increased 25.8% year-on-year; Positive trends in operating metrics continued in Q1 Company on track for 20% revenue g
Read more →APYXBOVIE MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2015 RESULTS 2015 Highlights - Sales increased 6.6% to $29.5 million - Gross margin expanded 180 basis points to 42.4%, from adjusted gross margin of 38.7% i
BOVIE MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2015 RESULTS - Sales increased 6.6% to $29.5 million - Gross margin expanded 180 basis points to 42.4%, from adjusted gross margin of 38.7% in 2014 - J-Plasma sales reached $1.3 million, up from $209,000 in 2014 - H
Read more →APYX3RD QTR EARNINGS exhibit991.htm Bovie Medical Reports Third Quarter 2015 Results Total Sales increased 15.3% year-on-year; Gross margin was 41.3% J-Plasma sales of $505,000 exceeded total sales for first ha
Bovie Medical Reports Third Quarter 2015 Results CLEARWATER, Fl. - NOV 4, 2015- Bovie Medical Corporation (NYSEMKT:BVX), a maker of medical devices and supplies and the developer of J-Plasma , a patented new surgical product, today announced results for the third quarter ended S
Read more →APYXQUARTER RESULTS exhibit991.htm Bovie Medical Reports Second Quarter 2015 Results Sales increased 4.7% year-on-year and 19% sequentially Gross margin expanded to 43.2%, compared with adjusted gross margin of 39.2% in 2Q14
Bovie Medical Reports Second Quarter 2015 Results CLEARWATER, Fl. - August 6, 2015- Bovie Medical (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma , a patented new surgical product, today announced results for the second quarter ended June 30, 20
Read more →APYXBOVIE MEDICAL CORPORATION ANNOUNCES CLOSING OF OVER-ALLOTMENT
BOVIE MEDICAL CORPORATION ANNOUNCES CLOSING OF OVER-ALLOTMENT OPTION CLEARWATER, FL - March 31, 2015 - Bovie Medical Corporation ("Bovie" or the "Company") (NYSE: BVX), a maker of medical devices and supplies and the developer of J-Plasma , a patented new surgical product, annou
Read more →APYXBOVIE MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2014 RESULTS Fourth Quarter Highlights Sales increased 22% year-on-year to $7.5 million Expanded R&D activities Bovie Ultimate Generator receives 510(k) appr
BOVIE MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2014 RESULTS Fourth Quarter Highlights Sales increased 22% year-on-year to $7.5 million Expanded R&D activities Bovie Ultimate Generator receives 510(k) approval Q4 sales of $73,000; Full year sales of $209
Read more →APYXhtm Bovie Medical Corporation Reports Third Quarter 2014 Results Third Quarter 2014 Highlights Total sales increased 17% year-over-year to $6.8 million Adjusted gross margin expanded to 41.3% Str
Bovie Medical Corporation Reports Third Quarter 2014 Results Third Quarter 2014 Highlights CLEARWATER, FL - November 6, 2014 - Bovie Medical Corporation (NYSE:BVX), a maker of medical devices and supplies, and the developer of J-Plasma , a patented new surgical product, today a
Read more →APYXBovie Medical Reports Second Quarter 2014 Results Second Quarter 2014 Highlights Sales increased 15% year-on-year to $6.9 million Adjusted 1 gross margin expanded to 39.2% Adjusted 2 operating loss was $520,000 versus $6
Bovie Medical Reports Second Quarter 2014 Results Second Quarter 2014 Highlights CLEARWATER, Fl. - August 5, 2014- Bovie Medical (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma , a patented new surgical product, announced results for the second
Read more →APYXAMENDED ORDER PRELIMINARY APPROVING SETTLEMENT exhibit991.htm IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION BRUCE A. ARBIT and MARK WINTERS, derivatively on behalf of Bovie Medical
IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF FLORIDA BRUCE A. ARBIT and MARK WINTERS, derivatively on behalf of Bovie Medical Corp., v. Case No: 8:11-cv-02020-T-30TBM ANDREW MAKRIDES, J. ROBERT SARON, GEORGE W. KROMER, MICHAEL G. NORMAN, AUGUST LENTRICCHI
Read more →APYXhtm Bovie Medical Names Peter Donato Chief Financial Officer CLEARWATER, Fl.
Bovie Medical Names Peter Donato Chief Financial Officer CLEARWATER, Fl. - May 06, 2014- Bovie Medical (NYSE:BVX), a maker of medical devices and supplies and the developer of J-Plasma , a patented new surgical product, announced today the appointment of Mr. Peter Donato, 44, as
Read more →APYXBovie Medical Reports Fourth Quarter and Full Year 2013 Results Names Jack McCarthy Chief Commercialization Officer Fourth Quarter 2013 Highlights o Appointed Robert L. Gershon Chief Executive Officer o Completed $7.0 Mi
Bovie Medical Reports Fourth Quarter and Full Year 2013 Results Names Jack McCarthy Chief Commercialization Officer Fourth Quarter 2013 Highlights Full Year 2013 Highlights CLEARWATER, Fl. -- March 31, 2014- Bovie Medical (NYSE:BVX), a maker of medical devices and supplies an
Read more →APYXBOVIE MEDICAL CORPORATION CLOSES STRATEGIC $7.0M EQUITY INVESTMENT THROUGH GREAT POINT PARTNERS APPOINTS ROBERT GERSHON NEW CEO TO PROMOTE GROWTH AND FUEL J-PLASMA EXPANSION Melville, New York
BOVIE MEDICAL CORPORATION CLOSES STRATEGIC $7.0M EQUITY INVESTMENT THROUGH GREAT POINT PARTNERS APPOINTS ROBERT GERSHON NEW CEO TO PROMOTE GROWTH AND FUEL J-PLASMA EXPANSION Melville, New York, December 13, 2013 - Bovie Medical Corporation (the "Company") (NYSE MKT: BVX), a ma
Read more →APYXSETTLEMENT AGREEMENT exhibit991.htm CONFIDENTIAL SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE This Confidential Settlement Agreement and Mutual General Release (the "Agreement"), is entered into as of this 28th day of
CONFIDENTIAL SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE This Confidential Settlement Agreement and Mutual General Release (the "Agreement"), is entered into as of this 28th day of December, 2011, by and between Bovie Medical Corporation ("Bovie"), Andrew Makrides ("Makrides
Read more →APYXBOVIE MEDICAL CORPORATION NAMES J. ROBERT SARON PRESIDENT; APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS Melville, New York
BOVIE MEDICAL CORPORATION NAMES J. ROBERT SARON PRESIDENT; APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS Melville, New York, March 21, 2011 Bovie Medical Corporation (the "Company") (NYSE-AMEX: BVX), a manufacturer and marketer of electrosurgical products, today announced
Read more →Competitive Position
How APYX ranks across every disease it competes inCompetitive Position is a premium feature
See how APYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial